abacavir, dolutegravir, and lamivudine drug combination

A combination of abacavir/dolutegravir/lamivudine

Also Known As:

Triumeq; abacavir - dolutegravir - lamivudine drug combination; abacavir, dolutegravir, lamivudine; abacavir, dolutegravir, lamivudine drug combination; abacavir-dolutegravir-lamivudine

Networked: 16 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Deeks, Emma D: 2 articles (04/2015 - 04/2015)
2.	Greig, Sarah L: 2 articles (04/2015 - 04/2015)
3.	Anghel, Lucretia: 1 article (02/2022)
4.	Arbune, Anca-Adriana: 1 article (02/2022)
5.	Arbune, Manuela: 1 article (02/2022)
6.	Fotea, Silvia: 1 article (02/2022)
7.	Niculet, Elena: 1 article (02/2022)
8.	Tatu, Alin Laurentiu: 1 article (02/2022)
9.	Al-Harthi, Lena: 1 article (01/2022)
10.	Arbieva, Zarema: 1 article (01/2022)

Related Diseases

1.	Infections 09/01/2023 - "This open-label post-marketing surveillance examined data from consecutive patients (aged ≥12 years) with HIV-1 infection receiving abacavir/dolutegravir/lamivudine according to locally approved prescribing information; treatment-naïve and treatment-experienced patients were permitted. " 09/01/2023 - "Abacavir/dolutegravir/lamivudine has been indicated in Korea since 2015 for treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination. " 01/01/2018 - "As Triumeq will be used on a regular basis as treatment for patients with HIV-1 infection, these intoxications are expected to be encountered more often." 09/01/2023 - "Results of this PMS study showed that abacavir/dolutegravir/lamivudine administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection." 12/15/2018 - "The fixed-dose combination (FDC) tablet formulation of abacavir/dolutegravir/lamivudine is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing ≥40 kg. Alternative formulations with acceptable palatability and convenient dosing are needed for children who require smaller doses and have difficulty swallowing tablets. "
2.	Disease Progression 11/01/2019 - "A larger international phase 3 trial will be deployed to assess the effect of Triumeq on overall survival and disease progression. " 11/01/2019 - "Consequently, the present study was undertaken to assess the safety and tolerability of long-term antiretroviral therapy (ART), Triumeq (abacavir, lamivudine, and dolutegravir) exposure in patients with ALS, and efficacy against biomarkers of disease progression. "
3.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 11/01/2019 - "Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial." 11/01/2023 - "The Molecular Link Between TDP-43, Endogenous Retroviruses and Inflammatory Neurodegeneration in Amyotrophic Lateral Sclerosis: a Potential Target for Triumeq, an Antiretroviral Therapy."
4.	Chemical and Drug Induced Liver Injury 01/01/2017 - "Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. "
5.	HIV Infections (HIV Infection) 01/01/2021 - "A 46-year-old man had been diagnosed with HIV infection and treated with combination antiretroviral therapy of dolutegravir/abacavir/lamivudine (Triumeq) for one year. " 01/01/2018 - "Triumeq is a single-tablet regimen for patients with HIV infection comprising dolutegravir, abacavir and lamivudine. "

Related Drugs and Biologics

1.	dolutegravir
2.	lamivudine drug combination abacavir
3.	Biomarkers (Surrogate Marker)
4.	Tablets
5.	abacavir (Ziagen)
6.	Lamivudine (Epivir)
7.	abacavir, dolutegravir, and lamivudine drug combination
8.	Integrases
9.	Reverse Transcriptase Inhibitors
10.	Bupropion (Wellbutrin)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Art Therapy
3.	Therapeutics